Martin Shkreli has said he would lower the price of Daraprim back down but hasn’t actually done it. He probably figures that if he can outlast the initial wave of negative publicity, people will…
A new study published recently by the Johns Hopkins University Bloomberg School of Public Health has linked an increase in premature births to a mother’s proximity to active, fracked natural gas wells.
Acelity Holdings has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
We scanned the Merrill Lynch stock coverage universe for specialty pharmaceutical stocks rated Buy and found three top companies that have been crushed.
Neurocrine Biosciences made waves in the market on Thursday morning after it announced positive results in a Phase 3 trial.
ThinkstockMallinckrodt PLC (NYSE: MNK) has been making waves in the market recently related to its guidance and it has caught the attention of one key analyst. Oppenheimer weighed in on Mallinckrodt in its most recent…
Aclaris Therapeutics debuted on the market in its initial public offering (IPO) on Wednesday morning.
These four top large cap biotechs are very good bets for investors looking to add high-quality companies with less volatility and binary clinical data risk.
Sarepta announced a public offering of more than 3 million shares of its common stock at a price to the public of $39.00 per share, with a value of up to more than $145…
ContraVir Pharmaceuticals led the bulls’ charge in the market on Monday, with shares practically doubling in what was thought to be a shaky health care sector.
A new report from Cowen points out that many skittish portfolio managers are anxiously awaiting third-quarter numbers to make sure that the biotech thesis is still in place.
Spark Therapeutics made history Monday morning when it announced successful Phase 3 results in gene therapy for a genetic disease.
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of October and added some color.
NovoCure entered the market sharply below the original anticipated price range and more than 15% before starting to recover.
Pacific Biosciences of California was surging in the market on Thursday despite a sharp downturn in the health care sector over the past quarter.